Semaglutide Generics
-
{
- All
- News
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
